IL-21 Genotyping for Secondary Autoimmunity Risk in MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multiple sclerosis (MS) treatments, such as alemtuzumab, often lead to secondary autoimmunity due to lymphopenia, with elevated IL-21 levels and specific genotypes (rs13151961, rs6822844, rs6840978) predicting increased risk, but the underlying factors and management strategies are not well understood.
Innovation Solution
Developing methods to identify MS patients at risk for secondary autoimmunity by measuring IL-21 levels or genotyping for specific SNPs, allowing for personalized treatment regimens and monitoring, including the use of IL-21 antagonists to mitigate autoimmunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lymphocyte depleting therapy (alemtuzumab) is administered to treat multiple sclerosis, then MS disease activity and disability accumulation are reduced, but secondary autoimmune diseases occur in 20-30% of patients
Solution Approach 1:
The patent applies preliminary action by measuring IL-21 levels and genotyping for SNPs (rs13151961, rs6822844, rs6840978) before administering alemtuzumab therapy. This pre-treatment assessment identifies patients at high risk for secondary autoimmunity, allowing clinicians to take preventive measures or select alternative treatments before the harmful effect occurs. The method enables risk stratification and informed decision-making prior to therapy initiation.
Solution Approach 2:
The patent implements feedback by using IL-21 level measurements and genotype information to guide treatment decisions. The assay results provide feedback on individual patient risk, allowing clinicians to adjust treatment plans based on predicted susceptibility to secondary autoimmunity. This feedback loop enables personalized medicine approaches where treatment is tailored to individual risk profiles.
2Object-affected harmful factors
If IL-21 levels are measured or genotyping is performed to identify at-risk patients, then secondary autoimmunity risk is reduced, but treatment complexity and monitoring requirements increase
Solution Approach 1:
The patent applies parameter changes by measuring specific biomarkers (IL-21 protein levels and SNP genotypes) that quantify individual risk for secondary autoimmunity. These measurable parameters transform the abstract concept of 'risk' into concrete, actionable data. By focusing on specific parameters (IL-21 concentration, presence of risk alleles), the method simplifies complex risk assessment into discrete, interpretable results that guide clinical decisions.
3Ease of operation
If alemtuzumab therapy is administered without prior risk assessment, then treatment accessibility is maintained, but patients develop autoimmune diseases months to years after dosing
Solution Approach 1:
The patent applies preliminary action by performing IL-21 measurements and genotyping before alemtuzumab administration. This pre-treatment risk assessment allows clinicians to identify high-risk patients before they undergo therapy, enabling preventive strategies or alternative treatment selection. The method shifts detection from post-treatment monitoring to pre-treatment prediction, eliminating the delayed detection problem.
Data Source
AI summary
The invention provides methods of diagnosing and treating multiple sclerosis (MS) patients, including methods of identifying and treating multiple sclerosis patients who are at increased risk of developing a secondary autoimmune disease following lymphocyte depletion, caused, e.g., by treatment with an anti-CD52 antibody. The increased risk may be linked to certain single nucleotide polymorphism genotypes that are indicative of elevated IL-21 levels. Also embraced are methods of selecting treatment regimens for MS patients, and reagents useful in the above methods.